The weekly average removes this noise and reveals the actual trend
Our clinical team is comprised of highly-skilled weight-loss experts and we are prepared to help you achieve your weight-loss goals with Contact us today
Ongoing guidance to keep you on track toward your goals
Seamless Integration Into Your Site WellSyncs technology seamlessly integrates into your existing website, enabling you to offer a full suite of GLP-1 services directly to your consumers

Sources New England Journal of Medicine: TripleHormone-Receptor Agonist Retatrutide for Obesity A Phase 2 Trial New England Journal of Medicine: Once-Weekly Semaglutide in Adults with Overweight or Obesity Eli Lilly: News Release: Lillys phase 2 retatrutide results published in The New England Journal of Medicine Clinical Trials Arena: Eli Lilly infiltrates anti-obesity market as Phase III trial for retatrutide begins Eli Lilly: News Release: Lillys tirzepatide shows additional 21.1% weight loss after 12 weeks of intensive lifestyle intervention, for a total mean weight loss of 26.6% from study entry over 84 weeks Semaglutide FDA Labels: Tirzepatide FDA Labels: Important Medical Information and Disclaimers Medical DisclaimerThis article, Retatrutide Weight Loss Results: Retatutride vs Tirzepatide vs Semaglutide , is for educational purposes only and is not intended to replace professional medical advice, diagnosis, or treatment

The compounded medication should be equivalent to branded options, but it is crucial to ensure you are obtaining it from a reputable source with a valid prescription